Natriuretic Peptides and Troponins: Sufficient Monitoring of Cancer Survivors?
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Chen Y, Chow E, Oeffinger K, Border W, Leisenring W, Meacham L
. Traditional Cardiovascular Risk Factors and Individual Prediction of Cardiovascular Events in Childhood Cancer Survivors. J Natl Cancer Inst. 2019; 112(3):256-265.
PMC: 7073918.
DOI: 10.1093/jnci/djz108.
View
2.
Ehrhardt M, Liu Q, Mulrooney D, Rhea I, Dixon S, Lucas Jr J
. Improved Cardiomyopathy Risk Prediction Using Global Longitudinal Strain and N-Terminal-Pro-B-Type Natriuretic Peptide in Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy. J Clin Oncol. 2024; 42(11):1265-1277.
PMC: 11095874.
DOI: 10.1200/JCO.23.01796.
View
3.
Leerink J, Feijen E, de Baat E, Merkx R, van der Pal H, Tissing W
. A Biomarker-Based Diagnostic Model for Cardiac Dysfunction in Childhood Cancer Survivors. JACC CardioOncol. 2024; 6(2):236-247.
PMC: 11103045.
DOI: 10.1016/j.jaccao.2024.02.008.
View
4.
Lustberg M, Reinbolt R, Addison D, Ruppert A, Moore S, Carothers S
. Early Detection of Anthracycline-Induced Cardiotoxicity in Breast Cancer Survivors With T2 Cardiac Magnetic Resonance. Circ Cardiovasc Imaging. 2019; 12(5):e008777.
PMC: 6516083.
DOI: 10.1161/CIRCIMAGING.118.008777.
View
5.
Armenian S, Lacchetti C, Barac A, Carver J, Constine L, Denduluri N
. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016; 35(8):893-911.
DOI: 10.1200/JCO.2016.70.5400.
View